Studien | Der Arzneimittelbrief

ARIES 1

Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies 1

ARIES 2

Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies 2

ARIES HM3

Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure

ARIOSO

Autoimmune gastRitis Italian netwOrk Study grOup

ARIPI

Age of Red blood cells In Premature Infants

ARISE

Aggressive Reduction of Inflammation Stops Events

ARisE

Assessment of psychosocial risk factors for patient with epilepsy

ARISE

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

ARISE

Australasian Resuscitation In Sepsis Evaluation randomised controlled trial

ARISE

QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD

ARISE

Study to evaluate the efficacy and safety of erenumab (AMG 334) compared to placebo in migraine prevention

ARISE

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

ARISE FLUIDS

Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis

ARISE I

Analysis of Revascularisation in Ischemic Stroke With EmboTrap I

ARISE II

Analysis of Revascularization in Ischemic Stroke With EmboTrap II

ARISE-HF

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

AriSLA

Fondazione italiana di ricerca per la Sclerosi Laterale Amiotrofica

ARISS

Albumin Replacement Therapy in Septic Shock

ARISTOTLE

Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation trial

ARIVA

Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS

Arizona

Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis

ARIZONA

Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications?

ARLG

Antibacterial Resistance Leadership Group

ARM

Impact of early versus late Artificial Rupture of Membranes during oxytocin induction of labour on the incidence of chorioamnionitis

ARMA

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

ARMADA

Advancing RSV Management And Disease Awareness

ARMADA

Anti-TNF Research study program of the Monoclonal Antibody D2E7

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction

ARMADA 4

Anti-TNF Research study program of the Monoclonal Antibody D2E7 4

ARMANI

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

ARMMS-T2D

Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes

ArMORR

Accelerated Mortality On Renal Replacement

ARMR

American Registry for Migraine Research

ARMS

Affirming At-Risk Minorities for Success

ARMS

APSAC Reocclusion Multicenter Study

Army STARRS

Army Study to Assess Risk and Resilience in Servicemembers

ARMYDA

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty study

ARMYDA PROVE

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort

ARMYDA-150 mg

Antiplatelet therapy for reduction of myocardial damage during angioplasty

ARMYDA-2

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty study 2

ARMYDA-2 SELECT

Antiplatelet therapy for reduction of myocardial damage during angioplasty SELECT substudy

ARMYDA-3

Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study 3

ARMYDA-4 RELOAD

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty RELOAD

ARMYDA-5 PRELOAD

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty PRELOAD

ARMYDA-6 MI

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction-6 MI

ARMYDA-7 BIVALVE

Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-7 Bivalirudin vs Heparin

ARMYDA-8 RELOAD-ACS

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-RELOAD-ACS

ARMYDA-9 CAROTID

Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study-9. Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

ARMYDA-ACS

Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study-Acute Coronary Syndromes

ARMYDA-ACS CAMs

Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules

ARMYDA-AGEs

Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris

ARMYDA-CAMs

Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules substudy

ARMYDA-CIN

Atorvastatin for Reduction of MYocardial Damage during Angioplasty--contrast-induced nephropathy

ARMYDA-CRP

Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention

ARMYDA-EPC

Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention

ARMYDA-PRO

Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity predicts Outcome

ARMYDA-RECAPTURE

Atorvastatin for Reduction of MYocardial Damage During Angioplasty

ARNASA

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease